Literature DB >> 10567335

The role of gene therapy for intimal hyperplasia of bypass grafts.

D G Cable1, J A Caccitolo, N Caplice, T O'Brien, R D Simari, R C Daly, J A Dearani, C J Mullany, T A Orszulak, H V Schaff.   

Abstract

BACKGROUND: Proliferation of the intima is an early lesion of saphenous vein graft disease. Early patency rates of radial artery grafts are acceptable, but little is known about their risk of intimal hyperplasia. METHODS AND
RESULTS: To develop a model of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial arteries (n=6, 8, and 10, respectively) in an organ culture with Roswell Park Memorial Institute 1640 (30% serum) for 0, 4, 7, 10, and 14 days. Quantitative histological studies were performed, and the average intimal-to-medial (I/M) ratio was calculated for each incubation interval. After 10 and 14 days of culture, the I/M ratio increased in the saphenous veins (P=0. 03, P=0.04 versus 0 day, respectively). No significant increase occurred in the I/M ratio in either the internal mammary or radial arteries. Next, the ability of adenoviral gene transfers to inhibit intimal hyperplasia in the saphenous veins was evaluated. Adenoviral-mediated gene transfer of nitric oxide synthase significantly reduced the I/M ratio at 14 days compared with vehicle (P=0.001) and virus (P=0.004) controls.
CONCLUSIONS: The human saphenous vein has a greater propensity for intimal hyperplasia than arterial grafts; the human radial artery behaves similarly to the internal mammary artery. In the future, gene therapy may augment nitric oxide synthase, limiting vein graft disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567335     DOI: 10.1161/01.cir.100.suppl_2.ii-392

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  Gene therapy for vein graft disease.

Authors:  D G Cable; H V Schaff
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

2.  Graft harvesting for revascularization in the head and neck.

Authors:  Terence E Johnson; John E Wanebo; Stephen W Bayles; Charles Y Liu
Journal:  Skull Base       Date:  2005-08

Review 3.  Gene therapy for the prevention of vein graft disease.

Authors:  Kevin W Southerland; Sarah B Frazier; Dawn E Bowles; Carmelo A Milano; Christopher D Kontos
Journal:  Transl Res       Date:  2012-12-27       Impact factor: 7.012

4.  Cyclic nucleotide phosphodiesterase 1 regulates lysosome-dependent type I collagen protein degradation in vascular smooth muscle cells.

Authors:  Yujun Cai; Clint L Miller; David J Nagel; Kye-Im Jeon; Soyeon Lim; Pingjin Gao; Peter A Knight; Chen Yan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-12-09       Impact factor: 8.311

5.  Increased aortic intimal proliferation due to MasR deletion in vitro.

Authors:  Hiba Alsaadon; Peter Kruzliak; Arthur Smardencas; Alan Hayes; Michael Bader; Peter Angus; Chandana Herath; Anthony Zulli
Journal:  Int J Exp Pathol       Date:  2015-02-10       Impact factor: 1.925

6.  Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia.

Authors:  Yujun Cai; David J Nagel; Qian Zhou; Katherine D Cygnar; Haiqing Zhao; Faqian Li; Xinchun Pi; Peter A Knight; Chen Yan
Journal:  Circ Res       Date:  2015-01-21       Impact factor: 17.367

7.  SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery.

Authors:  L Lipskaia; L Hadri; P Le Prince; B Esposito; F Atassi; L Liang; M Glorian; I Limon; A-M Lompre; S Lehoux; R J Hajjar
Journal:  Gene Ther       Date:  2012-07-05       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.